Systemic sclerosis: Recent insights

Joint Bone Spine

Volumn 82, Issue 3, 2015, Pages 148-153

  Elhai, Muriel ^a,b   Avouac, JérÔme ^a,b   Kahan, André ^a   Allanore, Yannick ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Cochin   (France)

Author keywords

Fibrosis; Pathogenesis; Raynaud's phenomenon; Systemic sclerosis; Treatment

Indexed keywords

ABATACEPT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; METHOTREXATE; MYCOPHENOLATE MOFETIL; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL DAMAGE; ENDOTHELIUM CELL; FIBROSIS; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; IMMUNE DEFICIENCY; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; MUSCULOSKELETAL DISEASE; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; PROGNOSIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SHORT SURVEY; SYSTEMIC SCLEROSIS; TREATMENT INDICATION; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE CELL; CLASSIFICATION; COMPLICATION; EARLY DIAGNOSIS; PATHOPHYSIOLOGY; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC;

ANTIRHEUMATIC AGENTS; EARLY DIAGNOSIS; FIBROSIS; HUMANS; PROGNOSIS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC;

EID: 84929276164     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.10.010     Document Type: Short Survey

References (64)

1. Van den Hoogen F., Khanna D., Fransen J., et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013, 72:1747-1755.
2. Ghatnekar A., Chrobak I., Reese C., et al. Endothelial GATA-6 deficiency promotes pulmonary arterial hypertension. Am J Pathol 2013, 182:2391-2406.
3. Avouac J., Vallucci M., Smith V., et al. Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis. Arthritis Res Ther 2013, 15:R55.
4. Maurer B., Distler A., Suliman Y.A., et al. Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Ann Rheum Dis 2013.
5. Derrett-Smith E.C., Dooley A., Gilbane A.J., et al. Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertension. Arthritis Rheum 2013, 65:2928-2939.
6. Manetti M., Guiducci S., Romano E., et al. Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis. Arthritis Res Ther 2013, 15:R165.
7. Kuwana M., Okazaki Y. Brief report: impaired in vivo neovascularization capacity of endothelial progenitor cells in patients with systemic sclerosis. Arthritis Rheumatol 2014, 66:1300-1305.
8. Elhai M., Avouac J., Kahan A., et al. Systemic sclerosis at the crossroad of polyautoimmunity. Autoimmun Rev 2013, 12:1052-1057.
9. Meunier M., Bazeli R., Feydy A., et al. Incomplete thymic involution in systemic sclerosis and rheumatoid arthritis. Joint Bone Spine Rev Rhum 2013, 80:48-51.
10. Avouac J., Elhai M., Tomcik M., et al. Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. Ann Rheum Dis 2013, 72:1089-1098.
11. Avouac J., Fürnrohr B.G., Tomcik M., et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2011, 63:800-809.
12. Avouac J., Elhai M., Allanore Y. Experimental models of dermal fibrosis and systemic sclerosis. Joint Bone Spine Rev Rhum 2013, 80:23-28.
13. Desallais L., Avouac J., Fréchet M., et al. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther 2014, 16:R157.
14. Joseph C.G., Darrah E., Shah A.A., et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 2014, 343:152-157.
15. Bhattacharyya S., Wei J., Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2012, 8:42-54.
16. Elhai M., Meune C., Avouac J., et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatol (Oxford) 2012, 51:1017-1026.
17. Tyndall A.J., Bannert B., Vonk M., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010, 69:1809-1815.
18. Onishi A., Sugiyama D., Kumagai S., et al. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 2013, 65:1913-1921.
19. Moinzadeh P., Fonseca C., Hellmich M., et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 2014, 16:R53.
20. Fransen J., Popa-Diaconu D., Hesselstrand R., et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011, 70:1788-1792.
21. Emad Y., Al-Sherbeni H., Ragab Y., et al. Arterial vasculopathy in systemic sclerosis: computerized tomography (CT) angiographic features of macrovascular and microvascular upper limbs arteries. Joint Bone Spine Rev Rhum 2014.
22. Avouac J., Fransen J., Walker U.A., et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011, 70:476-481.
23. Koenig M., Joyal F., Fritzler M.J., et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008, 58:3902-3912.
24. Smith V., Decuman S., Sulli A., et al. Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? a pilot study. Ann Rheum Dis 2012, 71:1636-1639.
25. Ennis H., Anderson M.E., Wilkinson J., et al. Calcium channel blockers for primary Raynaud's phenomenon. Cochrane Database Syst Rev 2014, 1:CD002069.
26. Montanelli G., Beretta L., Santaniello A., et al. Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series. Clin Exp Rheumatol 2013, 31:135-139.
27. Korn J.H., Mayes M., Matucci Cerinic M., et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004, 50:3985-3993.
28. Matucci-Cerinic M., Denton C.P., Furst D.E., et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011, 70:32-38.
29. Roustit M., Blaise S., Allanore Y., et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 2013, 72:1696-1699.
30. Allanore Y., Meune C., Vonk M.C., et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010, 69:218-221.
31. Shanmugam V.K., Steen V.D. Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol. 2012, 24:669-676.
32. Hudson M., Baron M., Tatibouet S., et al. International Scleroderma Renal Crisis Study Investigators. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-Results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum 2014, 43:666-672.
33. Avouac J., Airò P., Meune C., et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010, 37:2290-2298.
34. Avouac J., Huscher D., Furst D.E., et al. Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. Ann Rheum Dis 2014, 73:191-197.
35. Coghlan J.G., Denton C.P., Grünig E., et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2013.
36. Meune C., Avouac J., Airò P., et al. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 2011, 63:2790-2796.
37. Codullo V., Caporali R., Cuomo G., et al. Stress Doppler echocardiography in systemic sclerosis: evidence for a role in the prediction of pulmonary hypertension. Arthritis Rheum 2013, 65:2403-2411.
38. Lafyatis R. Application of biomarkers to clinical trials in systemic sclerosis. Curr Rheumatol Rep 2012, 14:47-55.
39. Van Bon L., Affandi A.J., Broen J., et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014, 370:433-443.
40. Volkmann E.R., Saggar R., Khanna D., et al. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. Arthritis Rheumatol 2014.
41. Galiè N., Corris P.A., Frost A., et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013, 62:D60-D72.
42. Pulido T., Adzerikho I., Channick R.N., et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013, 369:809-818.
43. Ghofrani H.-A., Galiè N., Grimminger F., et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013, 369:330-340.
44. Goh N.S.L., Desai S.R., Veeraraghavan S., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008, 177:1248-1254.
45. Nihtyanova S.I., Schreiber B.E., Ong V.H., et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014, 66:1625-1635.
46. Dieudé P., Guedj M., Truchetet M.E., et al. Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. Arthritis Rheum 2011, 63:1097-1105.
47. Dieudé P., Guedj M., Wipff J., et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 2009, 60:225-233.
48. Kowal-Bielecka O., Landewé R., Avouac J., et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009, 68:620-628.
49. Burt R.K., Oliveira M.C., Shah S.J., et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 2013, 381:1116-1124.
50. D'Alto M., Cuomo G., Romeo E., et al. Tissue Doppler imaging in systemic sclerosis: a 3-year longitudinal study. Semin Arthritis Rheum 2014, 43:673-680.
51. Coghlan G. Does left heart disease cause most systemic sclerosis associated pulmonary hypertension?. Eur Respir J 2013, 42:888-890.
52. Pieroni M., De Santis M., Zizzo G., et al. Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. Semin Arthritis Rheum 2014, 43:526-535.
53. Dinser R., Frerix M., Meier F.M.P., et al. Endocardial and myocardial involvement in systemic sclerosis - is there a relevant inflammatory component?. Joint Bone Spine Rev Rhum 2013, 80:320-323.
54. Di Cesare E., Battisti S., Di Sibio A., et al. Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). Eur J Radiol 2013, 82:e268-e273.
55. Vacca A., Meune C., Gordon J., et al. Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatol Oxf Engl 2014, 53:1172-1177.
56. Ghrénassia E., Avouac J., Khanna D., et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol 2014, 41:99-105.
57. Avouac J., Walker U., Tyndall A., et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 2010, 37:1488-1501.
58. Doré A., Lucas M., Ivanco D., et al. Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis. Arthritis Care Res 2013, 65:1385-1389.
59. Elhai M., Guerini H., Bazeli R., et al. Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings. Arthritis Care Res 2012, 64:1244-1249.
60. Frech T.M., Shanmugam V.K., Shah A.A., et al. Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol 2013, 31:166-171.
61. Jordan S., Distler J.H.W., Maurer B., et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2014.
62. Elhai M., Meunier M., Matucci-Cerinic M., et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2013, 72:1217-1220.
63. Prey S., Ezzedine K., Doussau A., et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol 2012, 167:1138-1144.
64. Van Laar J.M., Farge D., Sont J.K., et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014, 311:2490-2498.